Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a smaller surgery spare medullary thyroid cancer patients from lifelong pills?

NCT ID NCT07612293

Disease control Sponsor: Jonsson Comprehensive Cancer Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether removing only the cancerous part of the thyroid and nearby lymph nodes on one side is safe and effective for sporadic medullary thyroid cancer. Currently, all patients get the entire thyroid removed, which requires lifelong hormone pills and carries higher risks. The trial will enroll 100 adults to see if the less extensive surgery leads to remission and avoids the need for a second surgery.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Thyroid lobectomy with ipsilateral central neck dissection
What this could lead to
If successful, this could offer a less invasive surgical option for sporadic medullary thyroid cancer, avoiding lifelong thyroid hormone pills and reducing complication risks.
What could go wrong
This is an early-stage trial with only 100 participants. It may not prove that the less extensive surgery is as effective as total thyroidectomy, and some patients may still need a second surgery.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Apr 2032

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or female ≥ 18 years of age at time of diagnosis * Documentation of a medullary thyroid cancer diagnosis as evidenced by: * Thyroid fine needle aspiration biopsy with cytologist consistent with medullary thyroid cancer * Indeterminate cytology from thyroid fine needle aspiration with elevated serum calcitonin OR thyroid molecular testing consistent with medullary thyroid cancer * Written informed consent obtained from participant or participant's legal representative and ability for participant to comply with the requirements of the study * Appropriate candidate for thyroid lobectomy and/or total thyroidectomy Exclusion Criteria: * Indication for total thyroidectomy unrelated to medullary thyroid cancer: * Graves' disease * Symptomatic multinodular goiter * Contralateral symptomatic benign nodules * Ultrasound findings consistent with: * Cervical lymphadenopathy involving lateral neck or contralateral central neck * Suspicious thyroid nodules \> 1 cm that are Thyroid Imaging Reporting and Data Systems 2 (TIRADS2) or higher without fine needle aspiration (FNA) * Pure cystic and spongiform nodules do not require FNA * Patients with nodules that meet criteria above can elect to undergo FNA, and may enroll in study if benign cytology is noted * Identification of germline RET mutation on preoperative genetic testing

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Sporadic medullary thyroid cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Carcinoma, Medullary medullary thyroid gland carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Thyroid gland medullary carcinoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • UCLA / Jonsson Comprehensive Cancer Center

    Los Angeles, California, 90095, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.